Based on our own findings as well as emerging data in the CAR T-cell field, we reasoned that our clinical lead TAG72-CAR T cell’s superior performance against solid tumors is due to its ability to secrete high levels of IFNγ and enhance tumor cell killing. Here, IFNG is linked to neoplasm.